Targacept to Report Second Quarter 2011 Financial Results on August 4, 2011

WINSTON-SALEM, N.C.--(BUSINESS WIRE)-- Targacept Inc. (NASDAQ: TRGT), a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it will report financial results for the second quarter of 2011 on Thursday, August 4, 2011, after the U.S. financial markets close.

Management will discuss the second quarter financial results, provide an update on the company’s product development programs and business activities, and discuss expectations for the future via conference call at 5:00 p.m. Eastern Time on Thursday, August 4, 2011. The conference call may be accessed by dialing (800) 215-2410 for domestic participants and (617) 597-5410 for international callers (reference passcode 56958836). A replay of the conference call may be accessed from approximately 8:00 p.m. Eastern Time on August 4, 2011 through August 18, 2011 by dialing (888) 286-8010 for domestic callers and (617) 801-6888 for international callers (reference passcode 29670378).

A live audio webcast of the conference call will be accessible from the Investor Relations page of Targacept’s website, www.targacept.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled start time. An archived version of the webcast will also be available for replay on the Investor Calendar section of the Investor Relations page of Targacept’s website for at least two weeks following the call.

About Targacept

Targacept is developing a diverse pipeline of innovative NNR Therapeutics (TM) for difficult-to-treat diseases and disorders of the nervous system. NNR Therapeutics selectively modulate the activity of specific neuronal nicotinic receptors, a unique class of proteins that regulate vital biological functions that are impaired in various disease states. Targacept's lead program, TC-5214, is being co-developed with AstraZeneca and is in Phase 3 clinical studies as an adjunct treatment for major depressive disorder. Targacept leverages its scientific leadership and proprietary drug discovery platform Pentad™ to generate novel small molecule product candidates to fuel its pipeline and attract significant collaborations with global pharmaceutical companies. For more information, please visit www.targacept.com.

TARGACEPT

Building Health, Restoring IndependenceSM



CONTACT:

Targacept, Inc.
Alan Musso, 336-480-2186
SVP, Finance and Administration and CFO
[email protected]
or
Linnden Communications
Michelle Linn, 508-362-3087
[email protected]

KEYWORDS:   United States  North America  North Carolina

INDUSTRY KEYWORDS:   Health  Clinical Trials  Medical Devices  Pharmaceutical  Other Health  Professional Services  Finance  General Health

MEDIA:

Logo
 Logo

Suggested Articles

New real-world data from Lilly and BI show their SGLT2 med Jardiance topped GLP-1s at preventing heart failure hospitalization.

Following its headline-grabbing presentation at ESC, AZ is out with more data that support Farxiga use in non-diabetic heart failure patients.

An online pharmacy has again criticized FDA action after tipping off regulators to the existence of a dangerous impurity in Zantac and other antacids.